Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmDia: Empagliflozin for Diastolic Function in T2DM
NCT02932436Phase 4Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), diastolic dysfunction, sponsored by Johannes Gutenberg University Mainz. Started Oct 2016; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)diastolic dysfunction
Beyond the preview
Go deeper on NCT02932436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02932436.